Ambrx, Inc.

Kristine De Dios

Nick Knudsen

Vadim Kraynov

Jason Pinkstaff

Lorraine Sullivan

Amha Hewet

Ahma Hewet

Vadim Karynov

Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.

Modified relaxin polypeptides and their uses

Modified relaxin polypeptides and their uses thereof are provided.

Nucleic acids encoding modified relaxin polypeptides

Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides

Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid

Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain

Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.

Therapeutic uses of modified relaxin polypeptides

Method of treating heart failure with modified relaxin polypeptides

Modified relaxin polypeptides and their uses, including therapeutic uses thereof for the treatment of a fibrotic disorder or heart failure are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.

Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.

Growing community of inventors

San Diego, CA, United States of America

Kristine De Dios